Perimenopause as a longevity inflection point: Why the menopause transition shapes long-term women's health

Women in high-income countries live, on average, longer than men. They also spend more of those extra years with non-fatal but disabling conditions [1]. That healthy life expectancy gap has a location in time. For most women, the systems that shape the next thirty years (metabolic, cardiovascular, cognitive, musculoskeletal) are visibly reshaped between the ages of 40 and 60, in the years that bracket the menopausal transition.

These hormonal changes during perimenopause influence healthy aging, cardiovascular health, cognitive performance, metabolic resilience, and ultimately longevity.

This article describes what changes in the perimenopausal years, why preventive medicine matters more in this window than in any other, and what to focus on at each decade of the transition.

Perimenopause unfolds across several years. It begins, on average, in the early-to-mid forties and ends one year after the final menstrual period [2]. Its duration is variable: the median menopausal transition lasts around four years in women with later onset and rises to eight years or more in those whose transition begins earlier [3]. The Stages of Reproductive Aging Workshop (STRAW+10) framework divides the transition into early and late stages on the basis of changes in cycle length and follicle-stimulating hormone (FSH) variability [2].

Perimenopause is often described in clinical settings as a hormonal event, with hot flushes and irregular cycles as its public face. The underlying physiology is wider. The transition is driven by ovarian aging and a measurable decline in reproductive hormones, which together set off a system-wide recalibration of metabolism, sleep architecture, cognition, cardiovascular function, bone turnover, and immune regulation. The visible symptoms are the surface; the trajectory shifts underneath determine long-term health.

Women's metabolism shifts measurably across the transition. Insulin sensitivity declines and body composition changes during the menopausal transition, in part independently of chronological aging. The Study of Women's Health Across the Nation (SWAN), a large multi-ethnic cohort that has followed women through the transition for more than two decades, has documented accelerated gains in fat mass and central adiposity from the onset of the transition through to two years after the final menstrual period, after which the rate stabilises [4]. Lipid profiles change in parallel: total cholesterol, low-density lipoprotein, and apolipoprotein B all rise within the one-year window surrounding the final menstrual period, while most other cardiovascular risk markers change linearly with age [5].

The cumulative effect of these metabolic changes is to reset cardiovascular risk for the decades that follow.

Women's sleep changes measurably across the menopausal transition. Sleep disturbance is one of the most consistent symptoms reported during the transition, with prevalence rising from around a third of premenopausal women to roughly half by late perimenopause [6]. The change is not only in duration. Longitudinal polysomnographic studies have documented objective changes in sleep characteristics across the menopausal transition, including increased wakefulness after sleep onset, even when total sleep time appears preserved [7]. The downstream effect on next-day cognition, glucose regulation, and mood is well documented.

Women's cognitive health is among the most consistently noticed and least adequately investigated aspects of the transition. Performance on verbal memory tasks fails to improve through the early and late perimenopausal stages as it does in the pre- and postmenopausal stages, where the expected practice-effect gains are seen [8].

Women describe the pattern clearly when asked, and the mechanism appears to be physiological. Estrogen has direct effects on prefrontal cortical function and executive control, and its withdrawal during the transition is the most coherent mechanistic account of the cognitive complaints women bring to clinic [9]. Distinguishing perimenopausal cognitive change from other causes of cognitive decline is a clinical task that warrants more attention than it typically receives.

Before menopause, women have a lower incidence of cardiovascular disease than men of the same age. After menopause, the gap narrows. The American Heart Association's 2020 scientific statement on the menopause transition and cardiovascular disease risk identified the transition as a period of accelerated change in lipid profile, vascular function, and body composition that contributes to the rise in cardiovascular risk in the years that follow [10]. The implication for preventive medicine is direct: cardiovascular risk assessment should begin earlier in women than it commonly does, and the perimenopausal years are the natural point of intervention.

A fifth shift sits in the background of the other four. Bone mineral density at the lumbar spine falls at its fastest rate (around 2.5 per cent per year) across the three-year window starting one year before the final menstrual period, and cumulative loss across the decade spanning the transition averages close to ten per cent [11]. This trajectory is the foundation of later fracture risk.

Interventions started during the perimenopausal years act on systems that are still plastic. Resistance training in midlife improves bone mineral density and physical function in postmenopausal women across multiple systematic reviews [12]. Cardiometabolic monitoring catches insulin resistance and lipid changes when they are still reversible. Sleep restoration in midlife prevents the compounding cognitive cost of chronic fragmentation. The same interventions delivered in the late sixties or seventies do less, because the substrate is less responsive and the deficits have already accumulated.

This is the strategic argument for treating perimenopause as a clinical window for intervention.

The most useful work of the thirties is invisible at the time. Peak bone mass is reached by the late twenties, and lifestyle factors influence around twenty to forty per cent of adult peak bone mass; the goal in the thirties is to defend it, with weight-bearing exercise and adequate calcium and vitamin D intake [13]. Muscle mass is similarly defendable, and a baseline of resistance training laid down in the thirties pays compound interest. Cardiometabolic markers (fasting glucose, fasting insulin, a full lipid panel, blood pressure, waist circumference) deserve measurement at baseline and tracking over time; a single value filed and forgotten gives no information about trajectory. Women considering pregnancy should also be aware of ovarian reserve as a separate question from fertility itself; it informs planning without determining outcomes.

The thirties are also when sleep, exercise, and nutrition habits become durable, and the habits formed here are the ones that carry through the transition or fail to.

The early forties are when the perimenopausal transition typically begins, often before symptoms are recognised as such. A baseline workup at around age forty (full lipid profile, fasting glucose and insulin, HbA1c, thyroid function, vitamin D, iron studies, and an honest conversation about sleep and cycle regularity) gives a reference point against which later change can be read.

The forties are also when cardiovascular risk assessment should sharpen. Lipid changes that begin in the late perimenopausal years are easier to address before they become entrenched. Strength training, if it is not already in place, should be in place by the early forties; the trajectory of muscle and bone loss from this point onward is shaped by present action. Sleep complaints deserve clinical workup because the cost of chronic fragmentation compounds over decades.

This is also the decade to involve a preventive medicine team alongside a generalist. The questions being asked in the forties are different from those being asked in the thirties.

The fifties typically span the late perimenopausal and early postmenopausal years. The clinical priorities shift toward protection: maintaining the cardiovascular, metabolic, bone, and cognitive ground that has been built, and addressing where it has begun to give way.

Resistance training remains central; the evidence that it preserves bone density and lean mass in postmenopausal women is among the strongest in the preventive medicine literature [12]. Protein intake at the upper end of current recommendations (around 1.0 to 1.2 grams per kilogram of body weight per day in healthy older adults, rising to 1.2 to 1.5 grams in the presence of acute or chronic illness) supports muscle maintenance in this window [14]. Bone density assessment by DEXA is reasonable in the early postmenopausal years, earlier in women with risk factors. Cardiovascular monitoring should continue at higher cadence than in the previous decade. This is also the decade in which the difference between biological age vs chronological age becomes a useful clinical conversation in its own right.

This is also the decade in which menopausal hormone therapy (MHT) becomes a substantive clinical conversation. Current North American Menopause Society guidance is that, for healthy symptomatic women under the age of sixty and within ten years of the final menstrual period, MHT generally has a favourable benefit-risk profile and is an appropriate option for the management of vasomotor symptoms, sleep disruption, and genitourinary symptoms; the decision is individual and should account for personal and family medical history [15]. The framing in the public conversation has often been more polarised than the evidence warrants.

Translating this scientific evidence into clinical practice requires a structured and personalised preventive medicine approach. The future Nescens Female Health Program, delivered from a dedicated preventive medicine center, is built around the premise that the perimenopausal years deserve the same diagnostic and interventional rigour that cardiovascular medicine has long applied to the years around a cardiac event. The starting point is an integrative medicine assessment: a full picture of metabolic, hormonal, cardiovascular, bone, and cognitive baselines, with sleep and lifestyle factors mapped alongside. The interventions that follow are individual and revisited over time.

The clinical position is straightforward. There is no single intervention that defines longevity medicine in midlife women, and any clinic that markets one should be approached with caution. What works is a sequence of unremarkable, evidence-grounded interventions (strength training, protein adequacy, sleep restoration, cardiometabolic monitoring, considered hormone therapy where indicated) applied early, measured over time, and adjusted as the picture changes.

The years between forty and fifty-five are the period in which a woman's long-term healthspan is most actively decided. Treated as the inflection point they represent, they offer the largest clinical opportunity of any window in adult medicine. Understanding perimenopause symptoms, monitoring cardiovascular and metabolic health, protecting cognitive function, and implementing evidence-based preventive strategies can significantly improve healthy aging and female longevity. The interventions are unglamorous and the timelines are long, but they produce the greatest difference in how the next three decades unfold. How to age gracefully, in clinical terms, is mostly the cumulative effect of informed decisions taken at the right time.

The clinical position is straightforward. There is no single intervention that defines longevity medicine in midlife women, and any clinic that markets one should be approached with caution. What works is a sequence of unremarkable, evidence-grounded interventions (strength training, protein adequacy, sleep restoration, cardiometabolic monitoring, considered hormone therapy where indicated) applied early, measured over time, and adjusted as the picture changes.

The first signs of perimenopause often include changes in menstrual cycle regularity, sleep disturbances, mood fluctuations, hot flushes, fatigue, and cognitive symptoms such as difficulty concentrating or memory lapses.

Most women enter perimenopause in their early to mid-forties, although the timing varies considerably between individuals.

Yes. Hormonal fluctuations during perimenopause can influence attention, verbal memory, executive function, and overall cognitive performance.

The menopause transition is associated with changes in cholesterol levels, body composition, insulin sensitivity, and vascular function, which can contribute to an increased risk of cardiovascular disease.

Perimenopause is the transitional phase leading up to menopause and may last several years. Menopause is officially defined as twelve consecutive months without a menstrual period.